Suven Life Sciences Ltd has been granted three product patents.
The patents—one each from Australia, South Korea and China—are for its New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of select alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder, the Hyderabad-based company said in a release issued on Monday.
With these new patents, Suven has a total of seventeen (17) granted patents from Australia, thirteen granted patents from South Korea and thirteen (13) product patents from China.